Even a small number of duplicate patients can lead to a negative or failed trial and enrolling duplicate patients could result in an adverse event being attributed to the wrong trial. DupCheck provides a solution for this problem. 
 
Introduced under IMI's NewMeds project, DupCheck can improve compliance, reduce risks of misattributed safety signals and improve efficacy signals in clinical trials by screening out patients who are concurrently enrolled in other trials.   

The more studies using DupCheck, the more powerful it becomes as checks are made right across all participating studies.  The objective is to enrol as many companies and studies as possible and to facilitate this DupCheck is offered at no cost. 

To find out more about DupCheck and other IMI success stories, please click here.